1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplications
1995
An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin Lethality
Bianchi M, Ulrich P, Bloom O, Meistrell M, Zimmerman G, Schmidtmayerova H, Bukrinsky M, Donnelley T, Bucala R, Sherry B, Manogue K, Tortolani A, Cerami A, Tracey K. An Inhibitor of Macrophage Arginine Transport and Nitric Oxide Production (CNI-1493) Prevents Acute Inflammation and Endotoxin Lethality. Molecular Medicine 1995, 1: 254-266. PMID: 8529104, PMCID: PMC2229913, DOI: 10.1007/bf03401550.Peer-Reviewed Original ResearchConceptsNitric oxide synthaseL-arginine transportNO productionInflammatory responseBlood vesselsEndotoxin lethalityEDRF activityL-arginineArginine transportInhibitor of NOSLethal LPS challengeSystemic inflammatory responseNitric oxide productionSelective inhibitorDevelopment of carrageenanProduction of NOBackgroundNitric oxideEDRF responseMurine macrophage-like cell lineTetravalent guanylhydrazoneFootpad inflammationImportant homeostatic mechanismAcute inflammationLPS challengeMacrophage-like cell line